

A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION COMBINED EXAMINATION IN PSYCHIATRY

The American Board of Psychiatry and Neurology, Inc. (ABPN) has issued new, two-dimensional content specifications for the psychiatry, neurology and child neurology continuing certification examinations. Questions for the psychiatry, neurology and child neurology continuing certification combined examinations will conform to these new content specifications.

Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice.

The psychiatry, neurology and child neurology continuing certification combined content specifications can be accessed from the <u>Combined CC Exams section</u> of our website.

Candidates should use the new detailed content specifications as a guide to prepare for a continuing certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

The American Board of Psychiatry and Neurology, Inc. is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and continuing certification processes.

For more information, please contact us at questions@abpn.com or visit our website at <a href="ma



A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION COMBINED EXAMINATION IN PSYCHIATRY Content Blueprint

Number of o	Number of questions: 100		
	Dimension 1		
	Psychiatric Disorders and Topics		
01.	Developmental processes and development through the life cycle	1-3%	
02.	Disorders usually first diagnosed in infancy, childhood, or	1-3%	
	adolescence (Neurodevelopmental disorders)		
03.	Substance-related and addictive disorders	8-12%	
04.	Schizophrenia spectrum and other psychotic disorders	8-12%	
05.	Depressive disorders	8-12%	
06.	Bipolar and related disorders	6-8%	
07.	Anxiety disorders	7-9%	
08.	Obsessive-compulsive and related disorders	2-4%	
09.	Trauma- and stressor-related disorders	5-7%	
10.	Dissociative disorders	1-2%	
11.	Somatic symptom and related disorders	4-6%	
12.	Eating disorders	2-4%	
13.	Sleep-wake disorders	2-4%	
14.	Sexual dysfunctions	1-3%	
15.	Gender dysphoria	1-3%	
16.	Disruptive, impulse-control, and conduct disorders	1-2%	
17.	Personality disorders	6-8%	
18.	Paraphilic disorders	1-2%	
19.	Other conditions that may be a focus of clinical attention	1-2%	
20.	Neurocognitive disorders	7-9%	
21.	Neurologic disorders	4-6%	
22.	Dimension 2 topics without a corresponding Dimension 1 topic	2-4%	



A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION COMBINED EXAMINATION IN PSYCHIATRY Content Blueprint

Number of	Number of questions: 100	
	Dimension 2	
	Physician Competencies and Mechanisms	
A.	Neuroscience and mechanisms of disease	4-6%
B.	Behavioral and social sciences	4-6%
C.	Clinical aspects of psychiatric and neuropsychiatric disorders	17-23%
D.	Diagnostic procedures	17-23%
E.	Treatment	25-35%
F.	Interpersonal and communication skills	4-6%
G.	Professionalism, ethics, and the law	4-6%
H.	Practice-based learning and improvement	4-6%
I.	Systems-based practice	4-6%



A Member Board of the American Board of Medical Specialties (ABMS)

CONTINUING CERTIFICATION COMBINED EXAMINATION IN PSYCHIATRY Content Outline

	Dimension 1
	Psychiatric Disorders and Topics
01. De	velopmental processes and development through the life cycle (psychiatry and
nei	ırology)
a.	Infancy through adolescence
	i. Personality development
	ii. Developmental processes
	iii. Psychosocial influences
	iv. Other
b.	Adulthood
	i. Personality adaptation
	ii. Developmental processes
	iii. Psychosocial influences
	iv. Acquisition and loss of specific capacities
	v. Other
С.	Late life
	i. Personality adaptation
	ii. Developmental processes
	iii. Psychosocial influences
	iv. Acquisition and loss of specific capacities
	v. Other
02. Dis	orders usually first diagnosed in infancy, childhood, or adolescence
(ne	urodevelopmental disorders)
a.	Intellectual disability
b.	Language disorder
С.	Speech sound disorder
d.	Childhood-onset fluency disorder
e.	Social communication disorder
f.	Autistic spectrum disorder
g.	Attention deficit/hyperactivity disorder
h.	Specific learning disorder
i.	Developmental coordination disorder
j.	Stereotypic movement disorder



k. Tourette disorder	
l. Persistent motor or vocal tic disorder	
m. Provisional tic disorder	
03. Substance-related and addictive disorders	
a. Alcohol-related disorders	
b. Caffeine-related disorders	
c. Cannabis-related disorders	
d. Hallucinogen-related disorders	
e. Inhalant-related disorders	
f. Opioid-related disorders	
g. Sedative-, hypnotic-, or anxiolytic-related disorders	
h. Stimulant-related disorders	
i. Tobacco-related disorders	
j. Other (or unknown) substance-related disorders	
k. Gambling disorder	
04. Schizophrenia spectrum and other psychotic disorders	
a. Delusional disorder	
b. Brief psychotic disorder	
c. Schizophreniform disorder	
d. Schizophrenia	
e. Schizoaffective disorder	
f. Substance/medication-induced psychotic disorder	
g. Psychotic disorder due to another medical condition	
h. Catatonia	
i. Catatonic disorder due to another medical condition	
j. Unspecified catatonia	
k. Other specified schizophrenia spectrum and other psychotic disorder	
l. Unspecified schizophrenia spectrum and other psychotic disorder	
05. Depressive disorders	
a. Disruptive mood dysregulation disorder	
b. Major depressive disorder	
c. Persistent depressive disorder (dysthymia)	
d. Premenstrual dysphoric disorder	
e. Substance/medication-induced depressive disorder	
f. Depressive disorder due to another medical condition	
g. Other specified depressive disorder	
h. Unspecified depressive disorder	



06. Bip	olar and related disorders
a.	Bipolar I disorder
b.	Bipolar II disorder
c.	Cyclothymic disorder
d.	Substance/medication-induced bipolar and related disorders
e.	Bipolar and related disorder due to another medical condition
f.	Other specified bipolar and related disorder
g.	Unspecified bipolar and related disorder
07. An	riety disorders
a.	Separation anxiety disorder
b.	Selective mutism
c.	Specific phobia
d.	Social anxiety disorder (social phobia)
e.	Panic disorder
f.	Agoraphobia
g.	Generalized anxiety disorder
h.	Substance/medication-induced anxiety disorder
i.	Anxiety disorder due to another medical condition
j.	Other specified anxiety disorder
k.	Unspecified anxiety disorder
08. Ob	sessive-compulsive and related disorders
a.	Obsessive-compulsive disorder
b.	Body dysmorphic disorder
c.	Hoarding disorder
d.	Trichotillomania (hair-pulling disorder)
e.	Excoriation (skin-picking) disorder
f.	Substance/medication-induced obsessive-compulsive and related disorder
g.	Obsessive-compulsive and related disorder due to another medical condition
	Other specified obsessive-compulsive and related disorder
09. Tra	uma- and stressor-related disorders
a.	Reactive attachment disorder
b.	Disinhibited social engagement disorder
С.	Posttraumatic stress disorder
	Acute stress disorder
	Adjustment disorders
f.	Other specified trauma- and stressor-related disorder
10. Dis	sociative disorders



a.	Dissociative identity disorder
b.	Dissociative amnesia
C.	Depersonalization/derealization disorder
d.	Other specified dissociative disorder
e.	Unspecified dissociative disorder
11. So	matic symptom and related disorders
a.	Somatic symptom disorder
b.	Illness anxiety disorder
c.	Conversion disorder (functional neurological symptom disorder)
d.	Psychological factors affecting other medical conditions
e.	Factitious disorder
f.	Other specified somatic symptom and related disorder
g.	Unspecified somatic symptom and related disorder
12. Eat	ing disorders
a.	Pica
b.	Rumination disorder
c.	Avoidant/restrictive food intake disorder
d.	Anorexia nervosa
e.	Bulimia nervosa
f.	Binge-eating disorder
g.	Other specified feeding or eating disorder
13. Sle	ep-wake disorders
a.	Insomnia disorder
b.	Hypersomnolence disorder
c.	Narcolepsy
d.	Obstructive sleep apnea hypopnea
e.	Central sleep apnea
f.	Sleep-related hypoventilation
g.	Circadian rhythm sleep-wake disorders
h.	Non-REM sleep arousal disorders
i.	Nightmare disorder
j.	REM sleep behavior disorder
k.	Restless legs syndrome
l.	Substance/medication-induced sleep disorder
m.	Other specified insomnia disorder
n.	Unspecified insomnia disorder
0.	Other specified hypersomnolence disorder



p. Unspecified hypersomnolence disorder
q. Other specified sleep-wake disorder
r. Unspecified sleep-wake disorder
14. Sexual dysfunctions
a. Delayed ejaculation
b. Erectile disorder
c. Female orgasmic disorder
d. Female sexual interest/arousal disorder
e. Genito-pelvic pain/penetration disorder
f. Male hypoactive sexual desire disorder
g. Premature (early) ejaculation
h. Substance/medication-induced sexual dysfunction
15. Gender dysphoria
16. Disruptive, impulse-control, and conduct disorders
a. Oppositional defiant disorder
b. Intermittent explosive disorder
c. Conduct disorder
d. Pyromania
e. Kleptomania
f. Other specified disruptive, impulse-control, and conduct disorder
g. Unspecified disruptive, impulse-control and conduct disorder
17. Personality disorders
a. Paranoid personality disorder
b. Schizoid personality disorder
c. Schizotypal personality disorder
d. Antisocial personality disorder
e. Borderline personality disorder
f. Histrionic personality disorder
g. Narcissistic personality disorder
h. Avoidant personality disorder
i. Dependent personality disorder
j. Obsessive-compulsive personality disorder
k. Personality changed due to another medical condition
l. Other specified personality disorder
m. Unspecified personality disorder
n. General personality disorder
18. Paraphilic disorders



a.	Voyeuristic disorder
b.	Exhibitionistic disorder
C.	Frotteuristic disorder
d.	Sexual masochism disorder
e.	Sexual sadism disorder
f.	Pedophilic disorder
g.	Fetishistic disorder
h.	Transvestic disorder
i.	Other specified paraphilic disorder
j.	Unspecified paraphilic disorder
19. Otl	ner conditions that may be a focus of clinical attention
20. Ne	urocognitive disorders
a.	Delirium
b.	Other specified delirium
c.	Unspecified delirium
d.	Major or mild neurocognitive disorder due to Alzheimer disease
e.	Major or mild frontotemporal neurocognitive disorder
f.	Major or mild neurocognitive disorder with Lewy bodies
g.	Major or mild vascular neurocognitive disorder
h.	Major or mild neurocognitive disorder due to traumatic brain injury
i.	Substance/medication-induced major or mild neurocognitive disorder
j.	Major or mild neurocognitive disorder due to HIV infection
k.	Major or mild neurocognitive disorder due to prion disease
l.	Major or mild neurocognitive disorder due to Parkinson disease
m.	Major or mild neurocognitive disorder due to Huntington disease
n.	Major or mild neurocognitive disorder due to another medical condition
0.	Major or mild neurocognitive disorder due to multiple etiologies
p.	Unspecified neurocognitive disorder
21. Ne	urologic disorders
a.	Infections of the nervous system
b.	Vascular diseases
c.	Disorders of cerebrospinal and brain fluids
d.	Neuro-oncology
e.	Trauma
f.	Birth injuries and developmental abnormalities
g.	Genetic diseases of recognized biochemical abnormality
h.	Cerebral degenerations of childhood
11.	ocressial defendations of childripod



i. (Cranial nerve disorders
j. F	Peripheral neuropathies
k. <i>A</i>	Ataxias
l. I	Headache
m. I	Movement disorders
n. 9	Spinal cord diseases
0. 1	Neuromuscular junction disorders
p. 1	Myopathies
q. [Demyelinating diseases
r. E	Epilepsy and episodic disorders
s. I	Neurologic complications of systemic diseases
t. I	Neurotoxicology
u. F	Pain syndromes
v. (Other
22. Dim	ension 2 topics without a corresponding Dimension 1 topic



	Dimension 2
	Physician Competencies and Mechanisms
A.	Neuroscience and mechanisms of disease
	I. Neuroanatomy
	II. Cellular and molecular neurobiology
	III. Neuropathology
	IV. Genetics
	V. Neurochemistry
	VI. Neurophysiology
	VII. Chronobiology (e.g., biological rhythms, sleep)
	VIII. Neuroendocrinology and neuroimmunology
	IX. Other
В.	Behavioral and social sciences
	I. Psychology
	i. Experimental and behavioral psychology
	ii. Neuropsychology, cognitive psychology
	iii. Social psychology
	II. Sociology
	III. Anthropology, culture, ethnicity, and race
	IV. Psychoanalytic theory
	V. Spirituality
	VI. Biostatistics
	VII. Research design
	VIII. Other
C.	Clinical aspects of psychiatric and neuropsychiatric disorders
	I. Epidemiology
	II. Risk factors (predisposing factors)
	III. Precipitants
	IV. Protective factors
	V. Perpetuating factors
	VI. Presentation
	VII. Symptomotology
	VIII. Comorbidity
	IX. Differential diagnoses
	X. Course of illness
	XI. Prognosis



D.	Dia	gnostic procedures
	Ι	Psychiatric interview and mental status examination
	II.	Psychological testing
		Neuropsychological testing
		Diagnostic assessments and rating scales
	٧.	Laboratory monitoring
	VI.	Neuroimaging
	VII.	EEG
		. Sleep Studies
	IX.	Clinical neurologic examination
	Χ.	Biomedical laboratory testing
	XI.	Neurophysiologic testing
	XII.	Other
E.	Tre	atment
	l.	General principles of psychopharmacology and neuropharmacology
		i. Pharmacokinetics/pharmacodynamics
		ii. Drug interactions
		iii. Age, gender, and ethnicity issues
		iv. Genomics
	II.	Specific pharmacologic agents
		i. Tricyclics and heterocyclics
		ii. Monoamine oxidase inhibitors
		iii. Selective serotonin reuptake inhibitors (SSRI)
		iv. Selective norepinephrine reuptake inhibitors (NRI)
		v. Selective serotonin-norepinephrine reuptake inhibitors (SNRI)
		vi. Combined noradrenergic-dopaminergic agents (NDRI)
		vii. Noradrenergic and specific serotonergic agents (NaSSA)
		viii. Lithium
		ix. Atomoxetine
		x. Anticonvulsants
		xi. Benzodiazepines
		xii. Beta blockers
		xiii. Alpha agonists
		xiv. Typical antipsychotics
		xv. Atypical antipsychotics
		xvi. Psychostimulants
		xvii. Hypnotics and sedatives



xviii. Calcium channeers xix. Calcium channeer blockers xx. Dopamine agonists xxi. Anticholinergics xxii. Other agents used in the management of psychiatric patients xxiii. Other agents used in the management of neurologic patients III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic IV. Treatment of aggression i. Pharmacologic ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic vI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic VIII. Pharmacologic iii. Nonpharmacologic viii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. rTMS (repetitive transcranial magnetic stimulation)	
xxi. Dopamine agonists xxii. Anticholinergics xxiii. Other agents used in the management of psychiatric patients xxiii. Other agents used in the management of neurologic patients III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic iii. Nonpharmacologic iii. Nonpharmacologic v. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic vi. Treatment of pain i. Pharmacologic vii. Nonpharmacologic vii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viiii. Pharmacotherapy in special situations i. Renal disease iii. Hepatic disease iii. Hepatic disease iiii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback iii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vii. Neurosurgical approaches	xviii. Cognitive enhancers
xxi. Anticholinergics xxii. Other agents used in the management of psychiatric patients xxiii. Other agents used in the management of neurologic patients III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic iV. Treatment of aggression i. Pharmacologic ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic vII. Treatment of neuroleptic malignant syndrome i. Pharmacologic VIII. Pharmacologic iii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease iii. Hepatic disease iii. Hepatic disease iiii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback iii. Electroconvulsive therapy iiv. Chronotherapy iv. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	xix. Calcium channel blockers
xxii. Other agents used in the management of psychiatric patients xxiii. Other agents used in the management of neurologic patients III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic iii. Pharmacotherapy in special situations i. Renal disease iii. Hepatic disease iii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	xx. Dopamine agonists
xxiii. Other agents used in the management of neurologic patients III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic IV. Treatment of aggression i. Pharmacologic iii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic iii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic iii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic iii. Nonpharmacologic VIII. Treatment of neuroleptic malignant syndrome i. Pharmacologic iii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	xxi. Anticholinergics
III. Treatment of chemical dependence/abuse i. Pharmacologic ii. Nonpharmacologic IV. Treatment of aggression i. Pharmacologic iii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic iii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic iii. Nonpharmacologic VII. Treatment of pain i. Pharmacologic iii. Nonpharmacologic VIII. Treatment of neuroleptic malignant syndrome i. Pharmacologic iii. Nonpharmacologic VIII. Pharmacologic iii. Nonpharmacologic iii. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	xxii. Other agents used in the management of psychiatric patients
i. Pharmacologic ii. Nonpharmacologic IV. Treatment of aggression i. Pharmacologic ii. Nonpharmacologic v. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic v. Treatment of pain i. Pharmacologic ii. Nonpharmacologic vii. Nonpharmacologic iii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic viii. Nonpharmacologic iii. Nonpharmacologic iii. Nonpharmacologic iii. Nonpharmacologic iii. Nonpharmacologic iii. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	xxiii. Other agents used in the management of neurologic patients
ii. Nonpharmacologic IV. Treatment of aggression i. Pharmacologic ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacologic iii. Nonpharmacologic viii. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	III. Treatment of chemical dependence/abuse
IV. Treatment of aggression i. Pharmacologic ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic iii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic iii. Nonpharmacologic VIII. Treatment of neuroleptic malignant syndrome i. Pharmacologic viii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Pharmacologic
i. Pharmacologic ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic iii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic iii. Nonpharmacologic VIII. Pharmacologic iii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback iii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Nonpharmacologic
ii. Nonpharmacologic V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	IV. Treatment of aggression
V. Treatment of sleep disorders i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Pharmacologic
i. Pharmacologic ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Nonpharmacologic
ii. Nonpharmacologic VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	V. Treatment of sleep disorders
VI. Treatment of pain i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Pharmacologic
i. Pharmacologic ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Nonpharmacologic
ii. Nonpharmacologic VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	VI. Treatment of pain
VII. Treatment of neuroleptic malignant syndrome i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Pharmacologic
i. Pharmacologic ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Nonpharmacologic
ii. Nonpharmacologic VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	VII. Treatment of neuroleptic malignant syndrome
VIII. Pharmacotherapy in special situations i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Pharmacologic
i. Renal disease ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Nonpharmacologic
ii. Hepatic disease iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	VIII. Pharmacotherapy in special situations
iii. Pregnancy iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Renal disease
iv. Breast-feeding v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Hepatic disease
v. Tardive dyskinesia and extrapyramidal symptoms IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	iii. Pregnancy
IX. Augmentation strategies X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	iv. Breast-feeding
X. Nonpharmacologic somatic treatment i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	v. Tardive dyskinesia and extrapyramidal symptoms
 i. Biofeedback ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches 	IX. Augmentation strategies
ii. Electroconvulsive therapy iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	X. Nonpharmacologic somatic treatment
iii. Phototherapy iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	i. Biofeedback
iv. Chronotherapy v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	ii. Electroconvulsive therapy
v. Vagal nerve stimulation vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	iii. Phototherapy
vi. rTMS (repetitive transcranial magnetic stimulation) vii. Neurosurgical approaches	iv. Chronotherapy
vii. Neurosurgical approaches	v. Vagal nerve stimulation
3	vi. rTMS (repetitive transcranial magnetic stimulation)
XI Psychotherany	vii. Neurosurgical approaches
All 1 Sychotherapy	XI. Psychotherapy



		i.	Supportive
		ii.	Cognitive
		iii.	Behavioral
		iv.	Interpersonal
		٧.	Psychodynamic
		vi.	Psychoanalytic
		vii.	Couples
		viii.	Family
		ix.	Group
		х.	Crisis intervention
		xi.	Sex therapy
		xii.	Motivational interviewing
		xiii.	Other (e.g., hypnotherapy, critical incident debriefing)
	XII.	Psyc	chosocial interventions
		i.	Psychoeducation
		ii.	Vocational and occupational rehabilitation
		iii.	Self-help groups (e.g., AA, NA)
		iv.	Community-based treatment programs (e.g., halfway houses, day hospitals)
		٧.	Other
F.	Int	erpe	rsonal and communication skills
	I.	Con	nmunication with patients
	II.	Con	nmunication with other professionals
	III.	Con	nmunication with the public
	IV.	Con	nmunication with patients' families
	٧.	Con	nmunication with the healthcare team
	VI.	Man	agement of conflict
	VII.	Con	nmon errors in communication
G.	Pro	fess	ionalism, ethics, and the law
	I.	Sen	sitivity to diverse patient populations
	II.	Adh	erence to ethical principles (e.g., informed consent, research issues, clinical care)
	III.	Fati	gue management and work balance
	IV.	Prof	essional behavior
	٧.	Part	icipation in the professional community
			al issues in psychiatry
			of life issues
Н.	Pra	ctic	e-based learning and improvement
	Ι.		elopment and execution of lifelong learning
<u> </u>			



		i.	Self-assessment and self-improvement	
		ii.	Use of evidence in the clinical workflow	
	II.	Forr	mal practice-based quality improvement	
I.	Sy	stem	s-based practice	
	l.	Patient safety and the healthcare team		
		i.	Medical errors and improvement activities	
		ii.	Communication and patient safety	
		iii.	Regulatory and educational activities related to patient safety	
	II.	Res	ource management	
		i.	Parity	
		ii.	Access to care	
	III.	Con	nmunity-based care	
		i.	Community based-programs	
		ii.	Prevention	
		iii.	Recovery and rehabilitation	
	IV.	IV. Consultation to nonpsychiatric medical providers and nonmedical systems (e.g., milit		
		schools, businesses, forensic)		